Literature DB >> 29489737

Effects of Clonidine on the Cardiovascular, Renal, and Inflammatory Responses to Experimental Bacteremia.

Paolo Calzavacca1,2,3, Lindsea C Booth1, Yugeesh R Lankadeva1, Simon R Bailey4, Louise M Burrell5, Michael Bailey6, Rinaldo Bellomo2, Clive N May1.   

Abstract

INTRODUCTION: Supra-clinical doses of clonidine appear beneficial in experimental sepsis, but there is limited understanding of the effects of clonidine at clinically relevant doses.
METHODS: In conscious sheep, with implanted renal and pulmonary artery flow probes, sepsis was induced by infusion of live Escherichia coli. At 24 h, a high clinical dose of clonidine (HCDC) [1.0 μg/kg/h], a low clinical dose of clonidine (LCDC) [0.25 μg/kg/h] or vehicle, was infused for 8 h.
RESULTS: Animals developed hyperdynamic, hypotensive sepsis with acute kidney injury. The HCDC decreased heart rate (153 ± 6 to 119 ± 7 bpm) and cardiac output (5.6 ± 0.4 to 5.0 ± 0.4 L/min), with no reduction in mean arterial pressure (MAP). In contrast, LCDC increased cardiac output with peripheral vasodilatation. Both doses induced a large transient increase in urine output, an increase in plasma osmolality and, with the high dose, an increase in plasma arginine vasopressin. Sepsis increased plasma interleukin-6 (IL-6) and IL-10 and clonidine further increased IL-10 (1.6 ± 0.1 to 3.3 ± 0.7 ng/mL), but not IL-6. Clonidine reduced rectal temperature. During recovery from sepsis, MAP returned to baseline values more rapidly in the HCDC group (P < 0.001).
CONCLUSIONS: In hyperdynamic, hypotensive sepsis, the effects of clonidine at clinically relevant doses are complex and dose dependent. HCDC attenuated sepsis-related increases in heart rate and cardiac output, with little effect on arterial pressure. It also induced a water diuresis, increased AVP, reduced body temperature, and had an anti-inflammatory action. Low-dose clonidine had similar but less pronounced effects, except that it induced moderate vasodilatation and increased cardiac output.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29489737     DOI: 10.1097/SHK.0000000000001134

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  3 in total

1.  What's New in Shock, March 2019?

Authors:  Hongkuan Fan; Andrew J Goodwin
Journal:  Shock       Date:  2019-03       Impact factor: 3.454

2.  Clonidine for sedation in infants during therapeutic hypothermia with neonatal encephalopathy: pilot study.

Authors:  Estelle B Gauda; Raul Chavez-Valdez; Frances J Northington; Carlton K K Lee; Michelle A Rudek; Beatriz Guglieri-Lopez; Vijay Ivaturi
Journal:  J Perinatol       Date:  2021-09-16       Impact factor: 2.521

3.  Reversal of the Pathophysiological Responses to Gram-Negative Sepsis by Megadose Vitamin C.

Authors:  Yugeesh R Lankadeva; Rachel M Peiris; Nobuki Okazaki; Ian E Birchall; Anton Trask-Marino; Anthony Dornom; Tom A M Vale; Roger G Evans; Fumitaka Yanase; Rinaldo Bellomo; Clive N May
Journal:  Crit Care Med       Date:  2021-02-01       Impact factor: 9.296

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.